Sanofi teams with University of Tokyo for drug discovery

By Wang Fangqing

- Last updated on GMT

Sanofi teams with University of Tokyo for drug discovery

Related tags Japan Research Innovation

Sanofi will tap Japanese academics' personalised medicine knowhow under a new collaboration with the University of Tokyo's translational research initiative (TR).

Under the agreement, Sanofi’s Japan operation in Tokyo - Sanofi K.K.- will have the access to University's research mapping system, which provides details of each TR-related research project include early and unpublished data.

The French drugmaker expects the agreement to encourage close communications between researchers in the university and the company to promote the industry-academia partnership through combining TR’s discovery of drug targets and disease mechanism with its own technologies as well as rich research resources to develop novel drugs for the global market.

The research areas that are in Sanofi’s interest include oncology, diabetes, vaccines and rare diseases​” a Sanofi K.K spokesperson told Biopharma-reporter.

She said right now there is no specific project for the collaboration and the research is not limited to biomedicine or chemical drugs. It is also not disclosed which party will fund the research if a project is selected.

In a statement, Yuji Sato, head of R&D at Sanofi K.K., said the company is actively pushing open innovation and engages itself in turning revolutionary research into effective medicines.

Apparently Sanofi is not the only one having such a strategy. Other companies in Japan working with TR for the similar purpose include Novartis, Mitsubishi Tanabe, Novo Nordisk and Takeda

Related topics Bio Developments Bio-Outsourcing

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us

Products

View more

Webinars